Harnessing LRIG1-mediated inhibition of receptor tyrosine kinases for cancer therapy

Virginie Neirinckx; Hakan Hedman; Simone P. Niclou

doi:10.1016/j.bbcan.2017.02.007

Harnessing LRIG1-mediated inhibition of receptor tyrosine kinases for cancer therapy

Virginie Neirinckx, Hakan Hedman, Simone P. Niclou^*

^*Corresponding author for this work

Research output: Contribution to journal › Review article › peer-review

21 Citations (Scopus)

Abstract

Leucine-rich repeats and immunoglobulin-like domains containing protein 1 (LRIG1) is an endogenous feedback regulator of receptor tyrosine kinases (RTKs) and was recently shown to inhibit growth of different types of malignancies. Additionally, this multifaceted RTK inhibitor was reported to be a tumor suppressor, a stem cell regulator, and a modulator of different cellular phenotypes. This mini-review provides a concise and up-to-date summary about the known functions of LRIG1 and its related family members, with a special emphasis on underlying molecular mechanisms and the opportunities for harnessing its therapeutic potential against cancer.

Original language	English
Pages (from-to)	109-116
Number of pages	8
Journal	Biochimica et Biophysica Acta - Reviews on Cancer
Volume	1868
Issue number	1
DOIs	https://doi.org/10.1016/j.bbcan.2017.02.007
Publication status	Published - 1 Aug 2017

Keywords

Cancer
Ectodomain
Leucine-rich repeats and immunoglobulin-like domains containing protein 1
Nervous system
Receptor tyrosine kinase

Access to Document

10.1016/j.bbcan.2017.02.007

Cite this

@article{d8189f0648b648ea8a4f7b3bc3ec57dd,

title = "Harnessing LRIG1-mediated inhibition of receptor tyrosine kinases for cancer therapy",

abstract = "Leucine-rich repeats and immunoglobulin-like domains containing protein 1 (LRIG1) is an endogenous feedback regulator of receptor tyrosine kinases (RTKs) and was recently shown to inhibit growth of different types of malignancies. Additionally, this multifaceted RTK inhibitor was reported to be a tumor suppressor, a stem cell regulator, and a modulator of different cellular phenotypes. This mini-review provides a concise and up-to-date summary about the known functions of LRIG1 and its related family members, with a special emphasis on underlying molecular mechanisms and the opportunities for harnessing its therapeutic potential against cancer.",

keywords = "Cancer, Ectodomain, Leucine-rich repeats and immunoglobulin-like domains containing protein 1, Nervous system, Receptor tyrosine kinase",

author = "Virginie Neirinckx and Hakan Hedman and Niclou, \{Simone P.\}",

note = "Publisher Copyright: {\textcopyright} 2017 Elsevier B.V.",

year = "2017",

month = aug,

day = "1",

doi = "10.1016/j.bbcan.2017.02.007",

language = "English",

volume = "1868",

pages = "109--116",

journal = "Biochimica et Biophysica Acta - Reviews on Cancer",

issn = "0304-419X",

publisher = "Elsevier B.V.",

number = "1",

}

TY - JOUR

T1 - Harnessing LRIG1-mediated inhibition of receptor tyrosine kinases for cancer therapy

AU - Neirinckx, Virginie

AU - Hedman, Hakan

AU - Niclou, Simone P.

PY - 2017/8/1

Y1 - 2017/8/1

N2 - Leucine-rich repeats and immunoglobulin-like domains containing protein 1 (LRIG1) is an endogenous feedback regulator of receptor tyrosine kinases (RTKs) and was recently shown to inhibit growth of different types of malignancies. Additionally, this multifaceted RTK inhibitor was reported to be a tumor suppressor, a stem cell regulator, and a modulator of different cellular phenotypes. This mini-review provides a concise and up-to-date summary about the known functions of LRIG1 and its related family members, with a special emphasis on underlying molecular mechanisms and the opportunities for harnessing its therapeutic potential against cancer.

AB - Leucine-rich repeats and immunoglobulin-like domains containing protein 1 (LRIG1) is an endogenous feedback regulator of receptor tyrosine kinases (RTKs) and was recently shown to inhibit growth of different types of malignancies. Additionally, this multifaceted RTK inhibitor was reported to be a tumor suppressor, a stem cell regulator, and a modulator of different cellular phenotypes. This mini-review provides a concise and up-to-date summary about the known functions of LRIG1 and its related family members, with a special emphasis on underlying molecular mechanisms and the opportunities for harnessing its therapeutic potential against cancer.

KW - Cancer

KW - Ectodomain

KW - Leucine-rich repeats and immunoglobulin-like domains containing protein 1

KW - Nervous system

KW - Receptor tyrosine kinase

UR - https://www.scopus.com/pages/publications/85015092633

U2 - 10.1016/j.bbcan.2017.02.007

DO - 10.1016/j.bbcan.2017.02.007

M3 - Review article

C2 - 28259645

AN - SCOPUS:85015092633

SN - 0304-419X

VL - 1868

SP - 109

EP - 116

JO - Biochimica et Biophysica Acta - Reviews on Cancer

JF - Biochimica et Biophysica Acta - Reviews on Cancer

IS - 1

ER -

Harnessing LRIG1-mediated inhibition of receptor tyrosine kinases for cancer therapy

Abstract

Keywords

Access to Document

Other files and links

Fingerprint

Cite this